10x Genomics $TXG Shares Bought by Syon Capital LLC

Syon Capital LLC lifted its position in shares of 10x Genomics (NASDAQ:TXG) by 183.4% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 41,772 shares of the company’s stock after buying an additional 27,035 shares during the period. Syon Capital LLC’s holdings in 10x Genomics were worth $488,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Vanguard Group Inc. grew its position in 10x Genomics by 6.7% during the third quarter. Vanguard Group Inc. now owns 13,274,332 shares of the company’s stock valued at $155,177,000 after acquiring an additional 834,272 shares during the period. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of 10x Genomics by 12.2% during the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 6,017,963 shares of the company’s stock valued at $69,688,000 after buying an additional 654,597 shares during the period. Nikko Asset Management Americas Inc. raised its holdings in shares of 10x Genomics by 12.1% during the 2nd quarter. Nikko Asset Management Americas Inc. now owns 6,009,653 shares of the company’s stock valued at $69,532,000 after buying an additional 646,997 shares during the period. AQR Capital Management LLC lifted its position in 10x Genomics by 241.3% during the 2nd quarter. AQR Capital Management LLC now owns 4,137,801 shares of the company’s stock worth $47,916,000 after acquiring an additional 2,925,372 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in 10x Genomics by 13.4% in the 2nd quarter. Bank of America Corp DE now owns 3,023,489 shares of the company’s stock worth $35,012,000 after acquiring an additional 356,100 shares during the period. 84.68% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other 10x Genomics news, insider Benjamin J. Hindson sold 8,283 shares of the stock in a transaction on Monday, November 24th. The stock was sold at an average price of $19.00, for a total value of $157,377.00. Following the sale, the insider directly owned 432,605 shares of the company’s stock, valued at $8,219,495. This trade represents a 1.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Serge Saxonov sold 13,261 shares of the firm’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $19.00, for a total value of $251,959.00. Following the completion of the sale, the chief executive officer owned 1,021,556 shares in the company, valued at $19,409,564. The trade was a 1.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 33,432 shares of company stock valued at $635,208. Insiders own 9.39% of the company’s stock.

10x Genomics Price Performance

10x Genomics stock opened at $18.88 on Friday. 10x Genomics has a 12 month low of $6.78 and a 12 month high of $23.56. The company has a fifty day moving average price of $18.86 and a two-hundred day moving average price of $15.80. The company has a market cap of $2.39 billion, a PE ratio of -53.94 and a beta of 2.24.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings results on Thursday, February 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.06. 10x Genomics had a negative net margin of 6.77% and a negative return on equity of 6.89%. The company had revenue of $166.03 million for the quarter, compared to the consensus estimate of $160.35 million. During the same period last year, the firm posted ($0.40) EPS. The company’s revenue for the quarter was up .6% on a year-over-year basis. Equities research analysts anticipate that 10x Genomics will post -1.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on TXG. Deutsche Bank Aktiengesellschaft set a $17.00 price objective on shares of 10x Genomics and gave the company a “hold” rating in a research note on Friday, February 13th. TD Cowen boosted their price objective on shares of 10x Genomics from $18.00 to $19.00 and gave the stock a “hold” rating in a report on Friday, February 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 10x Genomics in a research report on Monday, December 22nd. Bank of America set a $21.00 price objective on 10x Genomics in a research note on Monday, January 12th. Finally, JPMorgan Chase & Co. upped their price target on shares of 10x Genomics from $13.00 to $15.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Four research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, 10x Genomics currently has a consensus rating of “Hold” and an average target price of $18.11.

About 10x Genomics

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.